FDA Approves New Taxotere Indication as First-Line Therapy for NSCLC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

BRIDGEWATER, New Jersey-The US Food and Drug Administration (FDA) has approved Taxotere (docetaxel, Aventis) as first-line therapy, in combination with cisplatin (Platinol), in patients with unresectable, locally advanced or metastatic non-small-cell lung cancer (NSCLC).

BRIDGEWATER, New Jersey—The US Food and Drug Administration (FDA) has approved Taxotere (docetaxel, Aventis) as first-line therapy, in combination with cisplatin (Platinol), in patients with unresectable, locally advanced or metastatic non-small-cell lung cancer (NSCLC).

Taxotere is the only agent indicated both for patients with newly diagnosed NSCLC, in combination with cisplatin, and for those with previously treated advanced NSCLC, as a single agent, Aventis said in a news release announcing the approval.

The FDA approval was based on a randomized controlled international phase III trial of 1,218 good performance status patients with previously untreated advanced NSCLC. Patients were randomized to receive Taxotere/cisplatin, Taxotere/carboplatin (Paraplatin), or a standard regimen of vinorelbine (Navel-bine)/cisplatin.

Patients in the Taxotere/cisplatin arm had a median survival of 10.9 months vs 10 months for vinorelbine/cisplatin (P = .035). The overall response rates were 31.6% for Taxotere/cisplatin vs 24.4% for vinorelbine/cisplatin. The Taxotere/carboplatin combination produced survival and response rates similar to those seen with vinorelbine/cisplatin.

Additional study analysis showed that the benefits from Taxotere/cisplatin were maintained in patients who were 65 years of age and older. This age group accounts for 68% of all lung cancer patients, according to data from the National Cancer Institute. Taxotere/cisplatin also showed clinical benefits in maintaining body weight, performance status, and pain management, compared with vinorelbine/cisplatin. 

Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content